Le tout premier patient international commence un traitement par lymphocytes T porteurs de récepteurs antigéniques chimériques (cellules CAR-T) récemment approuvé contre les tumeurs solides au Centre international de cancérologie Jiahui

The provided article text contains only a 404/error page and no substantive financial or market information. No company, macro, or policy details were available to assess impact or sentiment.

Analysis

The provided article text contains only a 404/error page and no substantive financial or market information. No company, macro, or policy details were available to assess impact or sentiment.